Literature DB >> 27532922

Stability of International Normalized Ratios in Patients Taking Long-term Warfarin Therapy.

Sean D Pokorney1, DaJuanicia N Simon1, Laine Thomas1, Bernard J Gersh2, Elaine M Hylek3, Jonathan P Piccini1, Eric D Peterson1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27532922     DOI： 10.1001/jama.2016.9356

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  11 in total

1.  Quality of warfarin management in primary care: Determining the stability of international normalized ratios using a nationally representative prospective cohort.

Authors:  Sharon Liu; Alexander Singer; Finlay A McAlister; William Peeler; Balraj S Heran; Neil Drummond; Donna P Manca; G Michael Allan; Christina Korownyk; Michael R Kolber; Michelle Greiver; Scott R Garrison
Journal:  Can Fam Physician       Date:  2019-06       Impact factor: 3.275

2.  Combination index of the concentration and in vivo antagonism activity of racemic warfarin and its metabolites to assess individual drug responses.

Authors:  Shuhei Kobayashi; Koji Ishii; Yasuko Yamada; Emi Ryu; Junya Hashizume; Seiichi Nose; Tetsuya Hara; Mikiro Nakashima; Kaname Ohyama
Journal:  J Thromb Thrombolysis       Date:  2019-04       Impact factor: 2.300

Review 3.  Highlights from the Tenth International Symposium of Thrombosis and Anticoagulation (ISTA X), September 22 and 23, 2017, Salvador, Bahia, Brazil.

Authors:  Renato D Lopes; Patricia O Guimarães; Mark Crowther; Elaine Hylek; Gilson S Feitosa-Filho; Luiz E Ritt; Nivaldo Filgueiras; David A Garcia
Journal:  J Thromb Thrombolysis       Date:  2018-05       Impact factor: 2.300

4.  Warfarin in Complex Older Patients: Have we Reached a Tipping Point?

Authors:  Jerry H Gurwitz
Journal:  J Am Geriatr Soc       Date:  2016-12-30       Impact factor: 5.562

5.  Association Between Warfarin Control Metrics and Atrial Fibrillation Outcomes in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation.

Authors:  Sean D Pokorney; DaJuanicia N Holmes; Laine Thomas; Gregg C Fonarow; Peter R Kowey; James A Reiffel; Daniel E Singer; James V Freeman; Bernard J Gersh; Kenneth W Mahaffey; Elaine M Hylek; Gerald V Naccarelli; Michael D Ezekowitz; Jonathan P Piccini; Eric D Peterson
Journal:  JAMA Cardiol       Date:  2019-08-01       Impact factor: 14.676

6.  Feasibility and safety of a 12-week INR follow-up protocol over 2 years in an anticoagulation clinic: a single-arm prospective cohort study.

Authors:  Andrea L Porter; Amanda R Margolis; Carla E Staresinic; Michael W Nagy; Rebecca R Schoen; Cheryl A Ray; Christopher D Fletcher
Journal:  J Thromb Thrombolysis       Date:  2019-02       Impact factor: 2.300

7.  Genotype-guided versus traditional clinical dosing of warfarin in patients of Asian ancestry: a randomized controlled trial.

Authors:  Nicholas L Syn; Andrea Li-Ann Wong; Soo-Chin Lee; Hock-Luen Teoh; James Wei Luen Yip; Raymond Cs Seet; Wee Tiong Yeo; William Kristanto; Ping-Chong Bee; L M Poon; Patrick Marban; Tuck Seng Wu; Michael D Winther; Liam R Brunham; Richie Soong; Bee-Choo Tai; Boon-Cher Goh
Journal:  BMC Med       Date:  2018-07-10       Impact factor: 8.775

8.  Oral anticoagulation therapy use in patients with atrial fibrillation after the introduction of non-vitamin K antagonist oral anticoagulants: findings from the French healthcare databases, 2011-2016.

Authors:  Géric Maura; Cécile Billionnet; Jérôme Drouin; Alain Weill; Anke Neumann; Antoine Pariente
Journal:  BMJ Open       Date:  2019-04-20       Impact factor: 2.692

9.  Time in therapeutic range and stability over time for warfarin users in clinical practice: a retrospective cohort study using linked routinely collected health data in Alberta, Canada.

Authors:  Finlay A McAlister; Natasha Wiebe; Brenda R Hemmelgarn
Journal:  BMJ Open       Date:  2018-01-29       Impact factor: 2.692

10.  Is Atrial Fibrillation Management as Simple as ABC?

Authors:  Xiaoxi Yao; Konstantinos C Siontis; Peter A Noseworthy
Journal:  J Am Heart Assoc       Date:  2020-05-06       Impact factor: 5.501
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.